Source:HongKong Economic TimesDate: 2024.04.12Chen Qiyu, Co-CEO of Fosun International, stated thatbenefitting from the return to normalcy in the post-pandemic era, the Happiness segment witnessed a rapid revenue growth, “various businesses such as gold & jewelry, tourism, and liquor demonstrated solid growth.”Entering the post-pandemic era, compan

Fidelidade, Fosun and Hospital Da Luz Reinforce their Commitment to InnovationAt this stage of the 6th edition of the Fidelidade, Fosun and Hospital da Luz Open Innovation Programme, the launch of the 7th edition was also announced at the Protechting Connect event, which strengthened the bridges to innovation.Lisbon, 11 April 2024 -The Fidelidade Group

Fidelidade, a subsidiary of Fosun Internationaland Portugal's leading insurer, announced on Wednesday (10 April) that its subsidiary, Luz Saúde, a private healthcare service provider had communicated to the market its plan to seek admission for the trading of its shares on the Euronext Lisbon stock exchange, as part of a planned public sale offer. If realized, t

On March 28th, Fosun International Chairman Guo Guangchang said at the 2023 annual results conference, “We are even more clear that we must focus on building sustainable, predictable, and enterprise with stable profit growth. Our core strategy revolves around directing our efforts towards enterprises where we have already established advantages. We used to “p

“We are even more clear that we must focus on building sustainable, predictable, and enterprise with stable growth. ”Speaking at the 2023 annual results conferenceon March 28th, Fosun International Chairman Guo Guangchang said, “We are even more clear that we must focus on building sustainable, predictable, and enterprise with stable profit growth.

(Hong Kong, Shanghai, 27 March 2024) Fosun International Limited (HKEX stock code: 00656, “Fosun International”), together with its subsidiaries (“Fosun” or the “Group”), today announced its annual results for the year ended 31 December 2023 (the “Reporting Period”).During the Reporting Period, the Group achieved a total revenue of RMB198.2 billion&#x

Dear shareholders,In 2023, the global economy showed signs of recovery, yetstillfilled with challenges. The entire team of Fosun worked together, actively seized opportunities and insisted on pursuing sustainable growth, resulting in the overall achievement of steady growth.As a global innovation-driven consumer group, the Group always adheres to the strategy

Results Highlights• Business Volume1reached RMB18,125.1 million, with a year-on-year growth of 19%, surpassing the 28% recorded in 2019, while revenue increased by 24% year-on-year to RMB17,151.8 million•Profit attributable to equity holders turned around to RMB307.2 million• Club Med achieved a Business Volume of RMB15,122.5 million, representing a 19% year-on-

Recently, an Innovation Passport designation has been awarded to serplulimab, Henlius’self-developed anti-PD-1 mAb (trade name in China: HANSIZHUANG), for the treatment of extensive stage small cell lung cancer (ES-SCLC) by the U.K. Innovative Licensing and Access Pathway Steering Group including the Medicines & Healthcare products Regulatory Agency (MHRA). This design